- Positive fasting pivotal bioequivalence results achieved for Letermovir 480 mg film-coated tablets using the US reference product.
- The milestone advances Adalvo’s US programme, with development for the EU market also progressing.
- Global Letermovir sales exceeded $1.1 billion in 2025, growing more than 80% in two years.
Zug, Switzerland, 20 November 2026 –Adalvo has achieved positive fasting pivotal bioequivalence (BE) results for its Letermovir 480 mg film-coated tablets using the US reference product, marking a significant milestone in the programme’s development for the US market.
Following the successful pivotal study, Adalvo is progressing dossier preparation and stability activities to maintain momentum towards future US regulatory submission and partner readiness. In parallel, the company is advancing the development work required to extend the programme opportunity to the EU market.
“Achieving positive pivotal BE results using the US reference product is an important milestone for our Letermovir programme. We are now focused on converting that success into the next stages of US development, while advancing the work required for Europe. This approach reflects our ambition to build a high-quality, partner-ready programme across key global markets.”
Letermovir is used for cytomegalovirus (CMV) prophylaxis in eligible adult haematopoietic stem cell transplant (HSCT) and kidney transplant recipients. Its preventive role and differentiated toxicity profile distinguish it from older antiviral options; approved indications and eligible populations vary by market.
According to IQVIA figures, global Letermovir sales exceeded $1.1 billion in 2025, with growth of over 80% in two years, highlighting the scale and momentum of the commercial opportunity.
Adalvo’s in-house capabilities and global supplier network support its approach to the technical and API sourcing challenges associated with this high-barrier molecule. With the US programme advancing and EU development underway, Adalvo is building a broader opportunity for partners, with Day-1 opportunities on the horizon.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.
